UMeWorld Announces Strategic Expansion in the U.S. and Forecasts Significant Revenue Growth
16 mai 2024 08h00 HE | UMeWorld Limited
HONG KONG, May 16, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTCPK: UMEWF) is pleased to announce a strategic plan for expansion in the United States. Having secured proprietary enzymatic...
22157.jpg
Reddit's Analysis on the Efficacy of FDA Approved Leading Weight Loss Drugs, Q4 2023 - Q2 2024: Focus on Semaglutide, Naltrexone-bupropion, Tirzepatide, Phentermine-topiramate, Liraglutide, Hydrogel
14 mai 2024 10h43 HE | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Reddit's Analysis on the Efficacy of Leading Weight Loss Drugs" report has been added to ResearchAndMarkets.com's offering.This comprehensive...
Will your health ins
Will your health insurance cover weight-loss medications? It depends on several factors, including where you live
08 mai 2024 11h23 HE | medicareresources.org
Minneapolis, MN, May 08, 2024 (GLOBE NEWSWIRE) -- Interest in medications prescribed for weight loss is skyrocketing, sparking consumer questions about whether health insurance covers these...
22157.jpg
Weight Loss/Weight Management (Obesity) Pipeline Insight, 2024: Drugs Under Development, Unmet Needs, Key Players, Collaborations, Licensing Agreement and Financing Details
08 mai 2024 05h39 HE | Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss/Weight Management (Obesity) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
22157.jpg
European $45 Billion Weight Loss Management Market Outlook to 2029: Rise of Personalised Nutrition and Wellness, Data-Driven Personalisation, Increasing Obesity Rates
07 mai 2024 05h07 HE | Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Europe Weight Loss Management Market Outlook, 2029" report has been added to ResearchAndMarkets.com's offering.Europe Weight Loss and Weight Management...
800 px horizontal logo.png
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
02 mai 2024 08h30 HE | Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
800 px horizontal logo.png
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01 mai 2024 09h00 HE | Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
GPT4 Social media image
UMeWorld Limited Updates Investors on Acquisition, Uplist and Relocation
30 avr. 2024 08h00 HE | UMeWorld Limited
MIAMI, April 30, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) is thankful to have the opportunity to update existing and future shareholders of the company operations and 2024 strategy...
Global Weight Loss Drugs Market
Weight Loss Drugs Market Trends Analysis 2018-2023 and Opportunities Forecast 2024-2033 Featuring Pfizer, Roche, Merck & Co, AbbVie, and Novartis
24 avr. 2024 04h12 HE | Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The weight loss drugs market size has...
ladybug_logo.png
Enhanced Inventory Management Solutions to Meet Rising E-Commerce Demand
23 avr. 2024 08h05 HE | LadyBug Resource Group, Inc.
Enhanced Inventory Management Solutions to Meet Rising E-Commerce Demand